Advertisement
Advertisement
NRSN
NeuroSense Therapeutics Ltd. Ordinary Shares
1.68
USDSponsored
+0.28
+20.43%
Nov 06, 15:59 UTC -5
Closed
After-Market
1.55
-0.13
-7.74%
NeuroSense Therapeutics Ltd. Ordinary Shares (NRSN) Earnings
NRSN Earnings Reports
Positive Surprise Ratio
NRSN beat 7 of 10 last estimates.
70%
Next Report
Date of Next Report
Mar 29, 2027
Estimate for Q4 26 (Revenue/ EPS)
--
/-$3.67
Implied change from Q2 26 (Revenue/ EPS)
--
/+74.76%
Implied change from Q4 25 (Revenue/ EPS)
--
/--
NeuroSense Therapeutics Ltd. Ordinary Shares earnings per share and revenue
On Sep 25, 2026, NRSN reported earnings of -2.10 USD per share (EPS) for Q2 26, beating the estimate of -3.26 USD, resulting in a 35.66% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -26.62% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of -3.67 USD, with revenue projected to reach -- USD, implying an increase of 74.76% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
INmune Bio Inc. Common stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.14
Actual
-$0.17
Surprise
-13.64%
Moderna, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$1.27
Actual
$0.38
Surprise
+129.79%
Vera Therapeutics, Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$1.65
Actual
-$1.30
Surprise
+21.33%
Novavax Inc
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.34
Actual
-$0.19
Surprise
+44.56%
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.31
Actual
$1.06
Surprise
+232.50%
Castle Biosciences, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.13
Surprise
+65.32%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.29
Actual
$0.03
Surprise
+110.09%
PUMA BIOTECHNOLOGY INC
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.09
Actual
$0.15
Surprise
+63.40%
Allogene Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.15
Actual
-$0.15
Surprise
+0.33%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.69
Actual
-$0.26
Surprise
+62.44%
FAQ
What were NeuroSense Therapeutics Ltd. Ordinary Shares's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, NeuroSense Therapeutics Ltd. Ordinary Shares reported EPS of -$2.10, beating estimates by 35.66%, and revenue of $0.00, 0% as expectations.
How did the market react to NeuroSense Therapeutics Ltd. Ordinary Shares's Q2 2026 earnings?
The stock price moved down -26.62%, changed from $6.95 before the earnings release to $5.10 the day after.
When is NeuroSense Therapeutics Ltd. Ordinary Shares expected to report next?
The next earning report is scheduled for Mar 29, 2027.
What are the forecasts for NeuroSense Therapeutics Ltd. Ordinary Shares's next earnings report?
Based on --
analysts, NeuroSense Therapeutics Ltd. Ordinary Shares is expected to report EPS of -$3.67 and revenue of -- for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.